Salt Lake City, Utah – October 5, 2026– DiscGenics, Inc., a privately held, late-stage clinical biopharmaceutical company developing regenerative cell-based therapies for musculoskeletal degeneration, today announced a leadership transition designed to support the Company’s continued advancement through late-stage clinical development and preparations for potential commercialization.
DiscGenics Announces Leadership Transition as IDCT Advances Through Pivotal Phase III Development
4 min read Premium comments
DiscGenics, Inc.Flagg FlanaganNajeeb Thomas MDRobert WynalekKevin T. Foley MDleadership transition
After 18 years of leadership and service, co-founder Flagg Flanagan is retiring from his roles as Chairman and Chief Executive Officer. Mr. Flanagan’s vision, perseverance, and commitment were instrumental in advancing IDCT from an early scientific concept into a pivotal Phase III clinical program. He will remain a member of the Board of Directors, allowing DiscGenics to continue benefiting from his experience, relationships, and institutional knowledge.
“Flagg recognized the transformative potential of IDCT and had the determination to advance it from an early scientific concept into a pivotal Phase III clinical program,” said Dr. Thomas. “His contribution to DiscGenics over nearly two decades has been extraordinary. This transition preserves the benefit of his experience while providing the focus, accountability, and strategic oversight the Company needs for its next stage of development.”
“It has been the privilege of my career to help build DiscGenics and advance IDCT to this important stage,” said Mr. Flanagan. “I am proud of what our team has accomplished and remain deeply committed to the Company, our mission, and the patients we hope to serve. I look forward to continuing to support DiscGenics as a member of the Board.”
To support DiscGenics’ next stage of development, the Board has separated the roles of Chairman and Chief Executive Officer. Najeeb Thomas, MD, has been appointed Chairman of the Board, Robert Wynalek has been appointed Interim Chief Executive Officer, and Kevin T. Foley, MD, will continue to serve as Chief Medical Officer and a member of the Board.
Since joining DiscGenics as Chief Operating Officer and a member of the Board in 2010, Mr. Wynalek has helped lead nearly every aspect of the Company’s development, including clinical operations, manufacturing, quality, regulatory execution, and corporate strategy. His deep institutional knowledge and record of operational leadership provide continuity as DiscGenics works to complete its pivotal Phase III program and prepare for the requirements of potential commercialization.
“DiscGenics has significant momentum, a deeply committed team, and a clear set of priorities,” said Mr. Wynalek. “I am honored to serve as Interim CEO and will remain focused on disciplined execution of our pivotal Phase III program, clinical manufacturing, and the operational and regulatory work needed to advance IDCT toward commercialization.”
Dr. Thomas is an internationally recognized neurosurgeon and experienced investor in early-stage technology, biotechnology, and medical device companies, with several successful exits and a record of leading fundraising rounds. He is Managing Member of Southern Brain & Spine and Co-founder, Chairman, and Medical Director of Crescent City Surgical Centre. He also serves on Geneoscopy’s Board and as Director and Vice-Chairman of the Louisiana State University Health Sciences Center Foundation. His investment, governance, and clinical expertise will support DiscGenics’ capital strategy and advancement toward potential commercialization.
A co-founder of DiscGenics, Dr. Foley will remain a member of the Board and continue serving as the Company’s Chief Medical Officer. He is a practicing neurosurgeon, medical technology entrepreneur, and internationally recognized innovator in minimally invasive spine surgery. Dr. Foley serves as Chairman of Semmes-Murphy Neurologic & Spine Institute and is a tenured professor of neurosurgery, orthopedic surgery, and biomedical engineering at the University of Tennessee. With more than 190 issued U.S. patents, he brings exceptional clinical, scientific, and innovation expertise as IDCT advances through Phase III development and the regulatory process.
About DiscGenics
DiscGenics is a privately held, late-stage clinical, biopharmaceutical company developing cell-based regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics’s first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable discogenic progenitor cell therapy for symptomatic, lumbar disc degeneration. IDCT is a mixture of live Discogenic Cells, which are a manufactured progenitor cell population derived from donated adult human intervertebral disc tissue, and a viscous carrier. IDCT has been granted regenerative medicine advanced therapy (RMAT) and Fast Track designations by the U.S. Food and Drug Administration. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics has a unique opportunity to offer a non-surgical, potentially regenerative solution for the treatment of patients suffering from the debilitating effects of back pain.
DiscGenics has developed a proprietary, commercial-scale, in-house allogeneic cell manufacturing process and built and qualified a cGMP facility at its Salt Lake City, Utah headquarters.
For more information, visit discgenics.com
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the therapeutic potential, regulatory status, commercialization timing, market opportunity, post-marketing commitments, and future development of IDCT. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including regulatory developments, clinical outcomes, manufacturing readiness, reimbursement decisions, commercialization execution, and other factors. DiscGenics undertakes no obligation to update these statements except as required by law.
Tagged: Press Release, Leadership
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
DiscGenics is strategically transitioning leadership to bolster its late-stage clinical development and prepare for potential commercialization of IDCT. The company aims to leverage new leadership expertise in capital strategy, operational execution, and regulatory affairs, while retaining institutional knowledge. This move supports disciplined execution of its pivotal Phase III program and readies its unique allogeneic cell therapy for market entry, capitalizing on RMAT and Fast Track designations.
- New leadership focuses on completing the pivotal Phase III program and scaling commercialization efforts for IDCT.
- The company maintains a proprietary, in-house cGMP manufacturing facility, critical for market readiness and supply chain control.
PhD Lens: Clinical and outcomes impact
DiscGenics is advancing IDCT, an allogeneic, injectable discogenic progenitor cell therapy, through pivotal Phase III development for symptomatic lumbar disc degeneration. Derived from donated adult human intervertebral disc tissue, IDCT aims to alleviate pain and restore function. The therapy holds Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, underscoring its potential as a non-surgical, regenerative solution for disc diseases.
- IDCT is composed of live Discogenic Cells and a viscous carrier, targeting degenerative spine conditions.
- The company utilizes a proprietary, commercial-scale, in-house allogeneic cell manufacturing process in a cGMP facility.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.